Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing s syndrome Summers SA; Nelson DHDiabetes 2005[Mar]; 54 (3): 591-602Metabolic syndrome X and type 2 diabetes share many metabolic and morphological similarities with Cushing's syndrome, a rare disorder caused by systemic glucocorticoid excess. Pathologies frequently associated with these diseases include insulin resistance, atherosclerosis, susceptibility to infection, poor wound healing, and hypertension. The similarity of the clinical profiles associated with these disorders suggests the influence of a common molecular mechanism for disease onset. Interestingly, numerous studies identify ceramides and other sphingolipids as potential contributors to these sequelae. Herein we review studies demonstrating that aberrant ceramide accumulation contributes to the development of the deleterious clinical manifestations associated with these diseases.|Animals[MESH]|Ceramides/chemistry/*metabolism/physiology[MESH]|Cushing Syndrome/metabolism/*physiopathology[MESH]|Diabetes Mellitus, Type 2/metabolism/*physiopathology[MESH]|Humans[MESH]|Insulin Resistance/physiology[MESH]|Metabolic Syndrome/metabolism/*physiopathology[MESH]|Molecular Structure[MESH] |